Galderma’s Relfydess(TM) (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
By API User
Ad hoc announcement pursuant to Art. 53 LR RelfydessTM (RelabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARLTM Technology, developed and manufactured by Galderma1,2 This positive decision is based on results from the phase III READY clinical trial program, which showed that RelfydessTM delivered sustained results for six months, combined with an … Continued